Valentina Zarka

机构：Universitätsklinikum Würzburg

发表论文 9 篇 · 总被引 71 次 · h-index 4

代表论文

• Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy (2024 · Hepatology · 被引 37)
• Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events (2024 · JHEP Reports · 被引 18)
• Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real‐World Analysis of the IMMUreal Cohort (2025 · Alimentary Pharmacology & Therapeutics · 被引 7)
• Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity (2025 · JHEP Reports · 被引 5)
• OS-112-YI Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapybased systemic therapy (2024 · Journal of Hepatology · 被引 4)
• Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC (2026 · JHEP Reports)